Literature DB >> 7638633

Hematopathologic findings in the myeloproliferative disorders.

J I Dickstein1, J W Vardiman.   

Abstract

In the preceding paragraphs, the features that define the various members of the CMPD have been reviewed. These features are summarized in Table 4. Knowledge of these guidelines will aid the clinician and pathologist in arriving at a proper classification; however, in most cases, it is the occasional patient whose clinical, laboratory, and morphologic findings lie across the different categories that unifies these CMPDs, and that provides the challenge which makes them interesting.

Entities:  

Mesh:

Year:  1995        PMID: 7638633

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report.

Authors:  Gyeongmin Jeong; Jinhyong Kim; Seeun Han; Jongmin Lee; Kyunghye Park; Chuiyong Pak; Ji-Hun Lim; Hee Jeong Cha; Hawk Kim; Jae-Cheol Jo
Journal:  Oncol Lett       Date:  2015-12-21       Impact factor: 2.967

2.  Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.

Authors:  Agnes Fütterer; Miguel R Campanero; Esther Leonardo; Luis M Criado; Juana M Flores; Jesús M Hernández; Jesús F San Miguel; Carlos Martínez-A
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

3.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 4.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Authors:  Douglas Tremblay; Abdulraheem Yacoub; Ronald Hoffman
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-26       Impact factor: 3.722

6.  Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.

Authors:  Min-Gu Kang; Hyun-Woo Choi; Jun Hyung Lee; Yong Jun Choi; Hyun-Jung Choi; Jong-Hee Shin; Soon-Pal Suh; Michael Szardenings; Hye-Ran Kim; Myung-Geun Shin
Journal:  Oncotarget       Date:  2016-08-30

7.  JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature.

Authors:  Sevastianos Chatzidavid; Nefeli Giannakopoulou; Panagiotis Theodorou Diamantopoulos; Eleni Gavriilaki; Panagiota Katsiampoura; Eleftheria Lakiotaki; Stratigoula Sakellariou; Nora-Athina Viniou; Georgios Dryllis
Journal:  Thromb J       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.